Members of the Cancer Prevention and Control Program (PC) conduct population sciences and chemoprevention research that has significant potential to reduce the cancer burden in Colorado, the Rocky Mountain Region and beyond. PC has three main focus groups: 1) behavioral research in primary and secondary prevention, 2) chemoprevention research, and 3) cancer outcomes and cancer survivorship research. During the current CCSG program members have made numerous contributions to the science of cancer prevention and control, including: 1) several large research clinical trials (RCTs) that have demonstrated the efficacy of tailored print materials to promote fruit and vegetable consumption, colorectal cancer screening and smoking cessation;2) a large school-based program and a monumental effort that targeted the outdoor winter recreation industry that successfully promoted sun protection;3) a robust program of laboratory research that has demonstrated the chemoprevention properties of silibinin in animal models for prostate, lung, colorectal, and bladder cancer, as well as grape seed extract for prostate and colon cancer;4) a large multi-site RCT demonstrating the efficacy of telephone counseling on psychosocial outcomes among breast cancer survivors;5) a large multi-site RCT that demonstrated the efficacy of a cognitive remediation program for young survivors of childhood cancer;6) two of the most definitive programs of research in cancer epidemiology that have examined and identified risk factors for breast cancer among Latinas, and nevus development among young children in Colorado, and 7) numerous exemplars of translational science and dissemination research in the areas of sun protection, diet, nutrition and physical activity, tobacco control, colorectal cancer screening and chemoprevention research. PC includes 31 Full Members and 32 Associate Members drawn from 17 academic departments and schools within the University of Colorado Denver, University of Colorado Boulder, the Veterans Administration (Denver), Colorado State University, Denver Health Medical Center, The Children's Hospital (Denver) and Kaiser Permanente of Colorado. During the current CCSG, program members have published 594 peer-reviewed cancer-related papers, compared to 306 during the previous CCSG. 37% of these publications were collaborative, with 23% being interprogrammatic or both interprogrammatic and intraprogrammatic. Peer reviewed, cancer-related funding has also increased from $8.9M (2005) to $13.3M in 2010. This represents a per capita increase of 140% from $269K to over $640K per member.

Public Health Relevance

To further reduce the cancer burden in the U.S., a robust program of research and translational science in cancer prevention and control is needed, which this program provides to UCCC, the State of Colorado and beyond.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994

Showing the most recent 10 out of 1634 publications